Key recommendations as new standard treatment:
-
Pertuzumab added to trastuzumab for adjuvant treatment of early HER2-positive breast cancer, based on new submitted data (reversing a 2018 decision); estimated impact: ~50 patients/year.
-
Polihexanid for acanthamoeba keratitis (~35 patients/year); the council notes no documented better clinical effect than prior magistral products, but higher cost, and will revisit the recommendation after two years.
-
Rucaparib for 1st line maintenance in advanced ovarian/fallopian tube/primary peritoneal cancer; effect described as comparable to niraparib (~100 patients/year), with a recommendation to use the cheaper option for at least 80% of patients.
-
Toripalimab + cisplatin and gemcitabine for recurrent/metastatic nasopharyngeal carcinoma; estimated 10–15 eligible patients/year.
Other notes include two direct placements (donidalorsen; nusinersen 50/28 mg), multiple myeloma guideline updates, two non-recommendations (ravulizumab; vutrisiran), and a clock-stop for glofitamab.
Read more at https://medicinraadet.dk/nyheder/2026/overblik-medicinradets-beslutninger-i-april-2026
